Edition:
United States

Opexa Therapeutics Inc (OPXA.OQ)

OPXA.OQ on NASDAQ Stock Exchange Capital Market

0.82USD
5 Dec 2016
Change (% chg)

-- (--)
Prev Close
$0.82
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
65,037
52-wk High
$4.92
52-wk Low
$0.50

OPXA.OQ

Chart for OPXA.OQ

About

Opexa Therapeutics, Inc. (Opexa) is a biopharmaceutical company. The Company is engaged in the development of a personalized immunotherapy with the potential to treat various illnesses, including multiple sclerosis (MS), as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on its... (more)

Overall

Beta: 2.28
Market Cap(Mil.): $10.50
Shares Outstanding(Mil.): 7.14
Dividend: --
Yield (%): --

Financials

  OPXA.OQ Industry Sector
P/E (TTM): -- 42.21 29.87
EPS (TTM): -1.24 -- --
ROI: -105.36 -1.09 14.95
ROE: -110.24 -2.39 16.29

BRIEF-Opexa Therapeutics receives notice from Ares Trading S.A. Unit of Merck Serono

* Opexa Therapeutics - On Nov 23, co received notice from Ares Trading S.A. Unit of Merck Serono

Nov 25 2016

BRIEF-Opexa Therapeutics reports qtrly loss per share of $0.28

* Opexa Therapeutics Inc reports qtrly option revenue $726,291 versus $726,291 last year

Nov 14 2016

BRIEF-Opexa Therapeutics qtrly loss per share $0.28

* Opexa -believes has sufficient liquidity to support current activities in winding down abili-t trial and for general operations

Nov 14 2016

BRIEF-Opexa Therapeutics announced workforce cut of about 40 pct on Nov. 2 - SEC Filing

* On November 2, 2016, co announced an approximately 40% reduction to company's then-current workforce

Nov 02 2016

BRIEF-Opexa Therapeutics says failed in mid-stage study

* Opexa therapeutics inc - on oc 28, co announced top-line results from its phase 2b "abili-t" clinical trial

Oct 28 2016

BRIEF-Opexa Therapeutics reports Q2 loss per share $0.30

* Opexa Therapeutics reports second quarter 2016 financial results and provides corporate update

Aug 11 2016

Competitors

Earnings vs. Estimates